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Genomics, especially multi-omics, has made precision medicine feasible. The completion and publicly 
accessible multi-omics resource with clinical outcome, such as The Cancer Genome Atlas (TCGA) is a 
great test bed for developing computational methods that integrate multi-omics data to predict patient 
cancer phenotypes. We have been utilizing TCGA multi-omics data to predict cancer patient survival, using 
a variety of approaches, including using prior-biological knowledge (such as pathways), and more recently, 
deep-learning methods. Over time, we have developed methods such as Cox-nnet, DeepProg, and two-stage 
Cox-nnet, to address the challenges due to multi-omics and multi-modality. Despite the limited sample size 
(hundreds to thousands) in the training datasets as well as the heterogeneity nature of human populations, 
these methods have shown significance and robustness at predicting patient survival in independent 
population cohorts. In the following, we would describe in detail these methodologies, the modeling results, 
and important biological insights revealed by these methods. 
Survival prediction using biological functions (pathways) as features 
Conventionally, Cox-PH models are used to fit or predict patient survival. When genomics data (eg. 
transcriptomics) are used as the input features, certain feature selection or regularization methods (ridge, 
lasso, or elastic net) are used to help reduce the number of input features used to build multi-variate Cox-
PH models. Many genes associated with the same biological functions are correlated. As a result, often 
times only a subset of genomics features is selected by the final model as potential biomarkers. Such 
approach has several potential issues for translational applications. One is that some features may not have 
clear or known biological functions, hampering them to be approved by FDA as biomarkers; another issue 
is that it may be difficult to ping-point the biological mechanism involved in patient survival.  
To address these issues, we have utilized a personalized, pathway-level prognosis modeling approach, and 
applied it to predict breast cancer patient survival in several omics platforms(Al-Akwaa et al. 2018; S. 
Huang et al. 2014, 2016; Fang et al. 2020). The idea is to utilize Pathifier (Drier, Sheffer, and Domany 
2013), an unsupervised dimension reduction method, to summary all genes’ values into a single value that 
represents the pathway, called Pathway Dysregulation Score (PDS), among each patient. One can then use 
pathway PDS as input features to replace the original genomics features, before the conventional Cox-PH 
based prognosis prediction. Pathifer is based on the method of “Principle Curve” (Hastie and Stuetzle 1989), 
where PDS for a given pathway is the distance from the starting point of the principle curve to another 
projected point on the curve from the patient data point in the hyper-space. We applied gene expression 
microarray datasets of breast cancers to predict patient survival in several independent testing cohorts, and 
obtained significant difference in patient survival risk groups (S. Huang et al. 2014). Worth mentioning, 
the genomics to biological function (pathway) based approach is also applicable to disease diagnosis. We 
built a pathway based breast cancer diagnosis model using metabolomics data, and validated it with very 
high accuracy (AUC=0.99) in TCGA RNA-Seq data(S. Huang et al. 2016) 
 
Multi-modal data-based survival prediction using Cox-nnet models 
Rather than relying on conventional Cox-PH model, we sought to renovate survival prediction with neural-
network (NN) models. Towards this we have developed Cox-nnet, a model where we add a fully connected 
NN to replace the linear model portion in Cox-PH(Ching, Zhu, and Garmire 2018).   With a relatively 
simple three-layer Cox-nnet model, we tested on 10 different cancers in TCGA RNA-Seq data, and Cox-
nnet achieved the same or better predictive accuracy compared to Cox-PH (with LASSO, ridge, and 
mimimax concave penalty), Random Forests Survival and CoxBoost methods. The hidden nodes Cox-nnet 
are surrogate features with prognosis predictive values, and it provides an alternative approach for survival-
sensitive dimension reduction. Moreover, Cox-nnet demonstrates richer biological information, at both the 
pathway and gene levels. 
We recently applied Cox-nnet to integrate multi-modal data types, exemplified by histopathology data and 
gene expression RNA-Seq data(Garmire et al. 2020). Compared to genomics data, pathological images are 
easily accessible data, however much more difficult to interpret. We first extended to predict patient 
survival using hepatocellular carcinoma (HCC) pathological images in TCGA. Again Cox-nnet based 
imaging predictions were more robust and accurate than Cox-PH model. We next used a two-stage Cox-
nnet complex model, where the first stage Cox-nnet models were built on pathological image and RNA-
Seq data respectively,  we then combined the hidden layer nodes as the input for the 2nd-stage Cox-nnet 
model, yelling  much more accurate prediction (C-index 0.77) than PAGE-Net, another complex, time-
consuming Convolutional neural network (CNN) model, which had a median C-index of 0.68. The 
combined model was more predictive than models using either data type alone. There was modest 
correlation between the imaging and RNA-Seq features, where genes correlated with top imaging features 
were enriched in carcinogenesis pathways or with known association with survival of HCC patients and/or 
morphology of liver tissue. 
Multi-omics data based stratified survival risk prediction using DeepProg models 
Parallel to the strategy of modeling patient survival using Cox-nnet built on the assumptions of proportional 
hazard ratios and regressions, we also sought for an alternative approach that predicted patient prognosis 
risks (rather than survival time) using multi-omics data. This resulted in DeepProg method (Chaudhary et 
al. 2018). In this method, different omics data types are stacked together as inputs for an auto-encoder of 
five layers, upon fitting the hidden nodes in the bottleneck layer (3rd layer) are individually fit with Cox-
PH model. The hidden features that are associated with survival are then used as the input for clustering. 
The best clusters are selected, and the patients are labeled into classes. Then classification model (eg SVM) 
is constructed using these labels and applied to predict other validation cohorts. We used RNA sequencing 
(RNA-Seq), miRNA sequencing (miRNA-Seq), and methylation data from hepatocellular carcinoma 
(HCC) patients in TCGA as the input of DeepProg, which yielded two optimal subgroups of patients with 
significant survival differences (C-index 0.68 and log-ranked p-values 7.13e-6). This multi-omics model 
was validated on five external datasets of various omics types with C-index between 0.67-0.82. Moreover, 
we found that the more aggressive subtype was associated with frequent TP53 inactivation mutations, as 
well as activated signaling pathways such as Wnt and Akt signaling pathways, whereas the patients with 
better survival have mostly metabolomic dysfunctions.  
We recently upgraded DeepProg with better and performance, first by fitting each omics data type with a 
separate auto-encoder model (Poirion, Chaudhary, and Garmire 2018). We most recently updated this 
method with an ensemble approach to further increase the stability (Poirion et al. 2019). Applying DeepProg 
on 32 cancer datasets from TCGA, we found that most cancers have two optimal survival subtypes, similar 
to the finding in HCC before. DeepProg yielded significantly (p-value=7.9e-7) better patient survival risk 
stratification than another multi-omics data integration Similarity Network Fusion (SNF). It also had 
excellent predictive accuracy in external validation cohorts, exemplified by two liver cancer (C-index 0.73 
and 0.80) and five breast cancer datasets (C-index 0.68-0.73). Pan-cancer analysis showed that patients 
with the poorest survival subtypes were enriched in genes functioning in extracellular matrix modeling, 
immune deregulation, and mitosis. Therefore, it is possible to not only construct prognosis models using 
multi-omics data, but also learn important biological mechanisms that govern the prognosis. 
DISCUSSION 
Patient survival prediction is clinical significant. New analytical approaches, such as machine-learning and 
deep-learning methods, will continue to drive forward the methodological improvement on multi-omics 
integration(S. Huang, Chaudhary, and Garmire 2017). To make “black-box” neural network models more 
interpretable and useful clinically, it is possible to combine prior biological knowledge with NN models. 
Patient survival risk stratification, rather than regression on survival time, is a practical consideration. We 
are currently comparing Cox-nnet (survival based) and DeepProg (classification based) approaches. Models 
that take into clinical phenotype, eg. individual subtype of cancer, can be more relevant (Chen et al. 2020). 
However, one must balance the practical issue of reduced sample size, in order to build such models, which 
may in turn have reduced predictability (esp. when applying deeplearning techniques). A good alternative 
may be including the patient clinical information as part of the model construction step, rather than sub-
setting the patients. Recent development in single cell technologies, especially in single-cell multi-omics 
technologies, provokes us to think deeper the heterogeneity even within the same patient samples (Ortega 
et al. 2017; Zhu et al., n.d.). Efforts devoted to deconvolute the heterogenous signatures from tumor and 
other cell types, such as immune cells (Q. Huang et al., n.d.), will hopefully improve the quality of input 
data for multi-omics integration at the population scale. Besides the accuracy of the model, other factors 
need to be considered, such as efficiency, adaptability, biological insights, and actionability. A good 
prognosis model ideally will not only predict patient survival accurately, but also provide insights that 
suggest personalized therapeutic treatments.  
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